WINNIPEG, MANITOBA--(Marketwire - October 02, 2008) - Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to update the market on its assay development progress for PSP94 and Vitronectin, the two proteins which comprise the Company's P2V™ prostate cancer test.
